Idorsia Pharmaceuticals Ltd.

• A trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis Recruiting
  2025-522922-11-00 Phase II 1 country ACT-1004-1239
• A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without pso… Ended
  2025-523051-64-00 Phase II 2 countries IDOR-1117-2520C
• A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease Ended
  2024-513884-20-00 Phase III 7 countries LUCERASTAT
• A drug-drug interaction trial in healthy female participants to investigate the effect of aprocitentan on combined hormonal contraceptives. Ended
  2024-517224-19-00 Phase I (Other) 1 country
• Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants Ended
  2023-506407-26-00 Phase I 1 country
• A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended
  2022-501246-30-00 Phase IV 2 countries DARIDOREXANT
• A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended
  2024-513885-20-00 Phase II 4 countries DARIDOREXANT

Showing 1–7 of 7 trials